ESPR - Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 199
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Sheldon L. Koenig | Pres, CEO & Director | 1.2M | N/A | 1966 |
| Mr. Benjamin O. Looker | Gen. Counsel | 550.35k | N/A | 1982 |
| Dr. JoAnne Micale Foody FACC, M.D. | Chief Medical Officer | 771.19k | N/A | 1966 |
| Mr. Benjamin Halladay M.B.A. | Chief Financial Officer | N/A | N/A | 1986 |
| Mr. Glenn P. Brame | Chief Technical Operations Officer | N/A | N/A | 1958 |
| Tiffany Aldrich M.B.A. | Associate Director of Corp. Communications | N/A | N/A | N/A |
| Ms. Betty Jean Swartz | Chief Strategy Officer | N/A | N/A | N/A |
| Mr. Eric J. Warren R.Ph. | Chief Commercial Officer | N/A | N/A | 1972 |
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Corporate governance
Esperion Therapeutics, Inc.’s ISS governance QualityScore as of 30 May 2023 is 7. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 8; Compensation: 9.
